Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Change in Accured Expenses (2021 - 2026)

Nuvectis Pharma has reported Change in Accured Expenses over the past 6 years, most recently at -$79000.0 for Q1 2026.

  • Quarterly results put Change in Accured Expenses at -$79000.0 for Q1 2026, down 416.0% from a year ago — trailing twelve months through Mar 2026 was $1.2 million (down 41.57% YoY), and the annual figure for FY2025 was $1.4 million, down 23.15%.
  • Change in Accured Expenses reached -$79000.0 in Q1 2026 per NVCT's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.9 million in Q4 2025 and bottomed at -$699000.0 in Q1 2023.
  • Median Change in Accured Expenses over the past 5 years was $80000.0 (2024), compared with a mean of $291235.3.
  • The largest annual shift saw Change in Accured Expenses surged 2256.52% in 2022 before it plummeted 416.0% in 2026.
  • Over 5 years, Change in Accured Expenses stood at -$305000.0 in 2022, then skyrocketed by 184.26% to $257000.0 in 2023, then surged by 593.77% to $1.8 million in 2024, then rose by 7.07% to $1.9 million in 2025, then tumbled by 104.14% to -$79000.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for NVCT at -$79000.0 in Q1 2026, $1.9 million in Q4 2025, and -$83000.0 in Q3 2025.